Oncimmune Holdings PLC (AIM:ONC, FRA:OCY) said it has signed an autoantibody profiling agreement with a global pharmaceutical company to evaluate the autoantibody profiles of patient samples in various autoimmune diseases.
The initial phase of this project, including the reporting of profiled data, is scheduled to complete by the end of 2021.
READ: Oncimmune hails three-year follow-up data from landmark early detection lung cancer trial
Under this agreement, Oncimmune will utilise its proprietary NavigAID autoimmune disease characterisation panel to explore the autoantibody profiles of patients with four key autoimmune diseases, namely systemic lupus erythematosus, Sjögren's syndrome, rheumatoid arthritis and sicca syndrome.
Oncimmune's customised autoimmune disease panel has been developed to explore the mechanisms of action, disease stratification and response prediction in clinical trials.
The programme is Oncimmune's second agreement with this partner and the firm said it further validates the value of Oncimmune's autoantibody biomarker profiling technology in supporting other companies.
"Today's agreement further demonstrates the strength of our ImmunoINSIGHTS service, the increasing recognition of Oncimmune's expertise in autoimmune disease, and our partnering strategy,” said chief executive Dr Adam M Hill.
“This new contract is also a good illustration of the growing uptake of our services, validating our decision to invest in the physical and human infrastructure of our platform to increase capacity significantly, with further pipeline conversion expected over the coming months and beyond."